Genscript Biotech Corporation
GNNSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $1 | $0 |
| % Growth | 1,466.6% | -94.1% | 25.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 61.8% | -105.3% | 54.7% | 52.3% |
| R&D Expenses | $0 | -$0 | $0 | $0 |
| G&A Expenses | $0 | -$0 | $0 | $0 |
| SG&A Expenses | $0 | -$0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Income | $0 | $0 | -$0 | -$0 |
| % Margin | 34.5% | 523.9% | -26.9% | -38.4% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | $3 | -$0 | -$0 |
| % Margin | -4.9% | 9,473% | -31.2% | -0.4% |
| EPS | -0.012 | 1.48 | -0.083 | -0.001 |
| % Growth | -100.8% | 1,889.6% | -9,088.9% | – |
| EPS Diluted | -0.012 | 1.44 | -0.083 | -0.001 |
| Weighted Avg Shares Out | 1 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 40.3% | 567.6% | -21% | -11.5% |